StreetInsider.com News Articles

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.

SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

Form 8-K Compass Therapeutics, For: Jun 10

Thu, 11 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26635492.html

Form 8-K Compass Therapeutics, For: Jun 10

Thu, 11 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26635492.html

Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens

Thu, 04 Jun 2026 05:22:56 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $10.00 price target on Compass Therapeutics (NASDAQ: CMPX).

The analyst commented, "We reiterate our Market Outperform and a $10 price target for Compass Therapeutics based on discounted EPS/revenue multiple analyses. Recently at ASCO, Compass presented clinical data from CTX-8371 (PD-1 x PD-L1 bsAb) demonstrating early activity in heavily pretreated post-IO NSCLC, TNBC, and classical HL. The bispecific showed a surprisingly clean safety/toxicity profile, with early signals suggesting a better profile compared to PD-(L)1 mAbs. With an FDA meeting to discuss the registrational path forward for tovecimig targeted for August, an expansion

Compass Therapeutics (CMPX) Reiterated at Buy by Stifel After ASCO Presentation

Mon, 01 Jun 2026 07:32:58 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $6.00 price target on Compass Therapeutics (NASDAQ: CMPX).

The analyst commented, " We believe the presentation of P1 singleagent CTX-8371 (PD-1xPD-L1 bispecific) dose-escalation data at this weekend’s ASCO meeting was minimally incremental given the recent publication of ASCO abstracts and prior qualitative management commentary re: safety/efficacy. We believe the durability of those responses observed to date in a heavily pretreated/IO-experienced patient population are impressive and believe granular safety/ tolerability data highlighting an absence of immune-mediated TRAEs highlights the unique mechanism of action anchoring CTX-8371 to the tumor microenvironment (vs. systemic inhibition within

Compass Therapeutics to Participate in Upcoming June Investor Events

Thu, 28 May 2026 07:30:00 -0400

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’

Compass Therapeutics to Participate in Upcoming June Investor Events

Thu, 28 May 2026 07:30:00 -0400

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’

Compass Therapeutics to Participate in Upcoming June Investor Events

Thu, 28 May 2026 07:30:00 -0400

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’

Compass Therapeutics to Participate in Upcoming June Investor Events

Thu, 28 May 2026 07:30:00 -0400

Details are as follows:

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs

Virtual/Replay availability: Presentations will be archived on Compass’

Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting

Thu, 21 May 2026 17:00:26 -0400

Compass Therapeutics Inc. (NASDAQ: CMPX) announced it will present phase 1 clinical data for CTX-8371 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.

The study evaluated CTX-8371, a dual checkpoint blocker targeting PD-1 and PD-L1, in 15 patients with advanced malignancies who had previously received immune checkpoint inhibitor treatment. Three patients achieved responses: one with triple-negative breast cancer showed greater than 90% reduction in target tumor lesions, one with Hodgkin lymphoma achieved a partial metabolic response, and one with non-small cell lung cancer achieved complete resolution of target lesions.

At the two

Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting

Thu, 21 May 2026 17:00:26 -0400

At the two

Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting

Thu, 21 May 2026 17:00:26 -0400

At the two

Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting

Thu, 21 May 2026 17:00:26 -0400

At the two

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Thu, 21 May 2026 17:00:00 -0400

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.
Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).
CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Thu, 21 May 2026 17:00:00 -0400

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.
Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).
CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Thu, 21 May 2026 17:00:00 -0400

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.
Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).
CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).